Effect of cognitive behavioral therapy for insomnia (CBT-I) and/or armodafinil on insomnia in cancer survivors.

Abstract

9531 Background: Insomnia is an underreported distressing side effect of cancer and its treatment, which can persist for months after treatment affecting the course of cancer survival. It exacerbates fatigue and results in reduced quality of life (QOL), allowing for the possibility that treatment of insomnia may improve associated symptoms and QOL. Although CBT-I is considered the nonpharmacologic treatment of choice for insomnia in the general population, it often results in short-term daytime sleepiness. The present study examines whether CBT-I in combination with a wakefulness promoting agent, armodafinil (A), results in greater overall reduction in insomnia in cancer survivors. Methods: Primary analyses examine if one or more of the intervention conditions (i.e., CBT-I, A, or both), when compared to placebo (P) group, reduce insomnia in cancer patients following completion of chemotherapy and/or radiotherapy. We report on 88 cancer survivors (mean age 56, 88% female, breast cancer 68%) randomized to o...